Pfizer Corporation

Matthew Richard Reese

Patrick Robert Verhoest

Bethany Lyn Kormos

Yuan Zhang

Jamison Bryce Tuttle

Martin Youngjin Pettersson

David Andrew Griffith

Dafydd Rhys Owen

Kevin James Filipski

Matthew Forrest Sammons

Karen Jean Coffman

Qingyi Yang

Luis Angel Martinez-Alsina

Leanne Marie Buzon

Rachel Jane Roth Flach

Travis T Wager

Samit Kumar Bhattacharya

Jaclyn Louise Henderson

Xiaojing Yang

Antonia Friederike Stepan

Paul Galatsis

Michelle Renee Garnsey

Ravi G Kurumbail

Liuqing Wei

Russell Alan Miller

Michael Aaron Brodney

Christopher Ryan Butler

Jotham Wadsworth Coe

Christopher John Helal

Neelu Kaila

Thomas Allen Chappie

Tarek A Samad

Joseph Scott Warmus

Brian Kenneth Raymer

Simone Sciabola

Michael L Vazquez

Mihir D Parikh

Jinshan Michael Chen

Kimberly O'Keefe Cameron

James M Duerr

Shenping Liu

Luis Angel Martinez Alsina

Kevin Francis Deboyace

Colin Richard Rose

Kiyoyuki Omoto

Described herein are compounds of Formula I, wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.

BCKDK inhibitors and/or degraders

Described herein are compounds of Formula I, wherein R, R, and Rare defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

BCKDK inhibitors

The invention relates to compounds of Formula I&#x2033; wherein R, R, R, R, p, q and q' are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

Nitrile-containing antiviral compounds

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.

Pyrrolo[2,3-d]pyrimidine derivatives

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R, R, R, R, R, R, R, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors

Growing community of inventors

Mystic, CT, United States of America

Matthew Richard Reese